NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free NKGN Stock Alerts $1.61 -0.37 (-18.69%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.60▼$1.9550-Day Range$0.80▼$2.5652-Week Range$0.78▼$12.88Volume543,810 shsAverage Volume2.75 million shsMarket Capitalization$36.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get NKGen Biotech alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About NKGen Biotech Stock (NYSE:NKGN)NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More NKGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKGN Stock News HeadlinesApril 25, 2024 | finance.yahoo.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25, 2024 | globenewswire.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 24, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 22, 2024 | finance.yahoo.comReplicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 22, 2024 | finance.yahoo.comWhat's Going On With Nano-Cap NKGen Biotech Stock On Monday?April 18, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 18, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 17, 2024 | investorplace.comNKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023April 11, 2024 | globenewswire.comNKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical ProgramsMarch 25, 2024 | globenewswire.comNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global ConferenceMarch 22, 2024 | investing.comNKGen Biotech appoints new chairperson amid leadership shuffleMarch 6, 2024 | investorplace.comWhy Is NKGen Biotech (NKGN) Stock Up 62% Today?March 4, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global ConferenceMarch 4, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global ConferenceFebruary 9, 2024 | msn.comAlana McNulty Exits NKGen Biotech’s Board and CommitteesFebruary 7, 2024 | finance.yahoo.comPassage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy CompaniesJanuary 3, 2024 | investing.comNKGen Biotech Inc (NKGN)December 29, 2023 | finance.yahoo.comNKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a TrialDecember 28, 2023 | finance.yahoo.comNKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s DiseaseDecember 27, 2023 | marketwatch.comNKGen Biotech Gets Clearance to Begin Alzheimer's Disease Treatment Trials in CanadaDecember 27, 2023 | markets.businessinsider.comNKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health CanadaDecember 27, 2023 | finance.yahoo.comNKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s DiseaseNovember 30, 2023 | seekingalpha.comNKGN NKGen Biotech, Inc.November 15, 2023 | seekingalpha.comNKGen Biotech GAAP EPS of -$2.48November 14, 2023 | finance.yahoo.comNKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business HighlightsSee More Headlines Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)7/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CUSIPN/A CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax Margin-76,940.53% Return on EquityN/A Return on Assets-97.14% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual Sales$80,000.00 Price / Sales459.05 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.60Miscellaneous Outstanding Shares22,810,000Free Float18,245,000Market Cap$36.72 million OptionableNot Optionable Beta0.54 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Paul Y. Song M.D. (Age 58)CEO & Chairman Comp: $36.58MMr. Sangwoo Park (Age 54)Executive Director Comp: $576kMr. James A. Graf (Age 59)Interim CFO Mr. Pierre Gagnon (Age 52)Chief Operating Officer Ms. Yoonmi KangVice President of Technical OperationsDr. Yong Man Kim Ph.D. (Age 59)Chief Scientific Officer Ms. Denise A. Chua CLSMBA, MT (ASCP), Vice President of Investor Relations & Corporate CommunicationsMs. Irene ChangVice President of Human ResourcesMr. Ryan Park C.F.A.SVP of Financial Planning & Analysis and Corporate StrategyMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSOKYO PharmaNASDAQ:OKYODyadic InternationalNASDAQ:DYAICidara TherapeuticsNASDAQ:CDTXEstrella ImmunopharmaNASDAQ:ESLAView All CompetitorsInsiders & InstitutionsUniversity of ChicagoBought 550,000 shares on 3/14/2024Ownership: 2.513%Paul Y SongBought 75 shares on 12/6/2023Total: $249.00 ($3.32/share)Paul Y SongBought 244 shares on 11/27/2023Total: $702.72 ($2.88/share)Paul Y SongBought 100 shares on 11/21/2023Total: $280.00 ($2.80/share)James A GrafBought 10 shares on 11/20/2023Total: $29.40 ($2.94/share)View All Insider TransactionsView All Institutional Transactions NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed in 2024? NKGen Biotech's stock was trading at $2.75 on January 1st, 2024. Since then, NKGN shares have decreased by 41.5% and is now trading at $1.61. View the best growth stocks for 2024 here. When is NKGen Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024. View our NKGN earnings forecast. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NKGN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
